Fusion protein · Immune activation, directed at PRAME and CD3 (CD3E) · developed by Immunocore
Brenetafusp is a soluble T-cell receptor fused to an anti-CD3 single-chain variable fragment. The T-cell receptor moiety binds PRAME on tumor cells while the anti-CD3 moiety binds T lymphocytes, cross-linking them so that cytotoxic T cells kill PRAME-expressing cells. It is studied in advanced solid tumors and advanced melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06112314 | Phase 3 | Advanced Melanoma | Recruiting | IMCR |
| NCT04262466 | Phase 1/2 | Select Advanced Solid Tumors | Active not recruiting | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced MelanomaSelect Advanced Solid Tumors
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →